Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S0140-6736(13)61200-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Reporting of concomitant and rescue topical therapies in atopic dermatitis randomised controlled trials evaluating a systemic treatment: a scoping review.
Br J Dermatol
January 2025
Centre of Evidence Based Dermatology, School of Medicine, Faculty of Medicine & Health Sciences, University of Nottingham, UK.
Background: Randomised controlled trials (RCTs) evaluating new systemic treatments for atopic dermatitis (AD) have increased dramatically over the last decade. These trials often incorporate topical therapies either as permitted concomitant or rescue treatments. Differential use of these topicals post-randomisation introduces potential bias as they may nullify or exaggerate treatment responses.
View Article and Find Full Text PDFGeneralizability of Randomized Controlled Trials to Routine Clinical Care in Ulcerative Colitis.
Inflamm Bowel Dis
January 2025
Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, 5th Floor Cal Wenzel Precision Health Building, 3280 Hospital Drive NW, Calgary, AB T2N 4Z6, Canada.
Background: Historically, randomized controlled trials (RCTs) have been criticized for being poorly generalizable to patients with ulcerative colitis (UC) evaluated in routine care. We aimed to evaluate the proportion of patients with UC starting an advanced therapy who would be eligible to participate in phase 3 registrational UC RCTs.
Methods: We conducted a retrospective cohort analysis of UC patients starting vedolizumab, ustekinumab, or tofacitinib at 2 IBD clinics at the University of Calgary.
Addressing Period Poverty: Evaluating a Free Period Product Program in a University Setting.
Health Promot Pract
January 2025
Department of Public Health, College of Health and Human Sciences, Purdue University, West Lafayette, IN, US.
Period poverty, characterized by inadequate access to menstrual health resources and education, detrimentally affects school attendance, academic performance, and individual health. Recent studies have revealed nearly one-fifth of college-enrolled women experienced period poverty in the past year, highlighting the urgency of addressing this issue. Through our study at Purdue University, we evaluated the effectiveness of a free pad and tampon program aimed at reducing period poverty.
View Article and Find Full Text PDFEfficacy of rituximab as second-line therapy for autoimmune encephalitis: A systematic review and meta-analysis.
Heliyon
January 2025
Department of Emergency, Dali Bai Autonomous Prefecture People's Hospital, Dali, Yunnan, 671000, China.
Background: Approximately 20%-50 % of individuals with autoimmune encephalitis (AE) demonstrate suboptimal responses to first-line therapies, leading to persistent neurological deficits and the need for second-line interventions. Although rituximab has shown potential as an alternative treatment in AE, the existing evidence remains insufficient. This study systematically evaluated and meta-analyzed the efficacy of rituximab in AE patients who either failed or exhibited inadequate responses to first-line treatments, aiming to refine and optimize therapeutic strategies for AE.
View Article and Find Full Text PDFRisk prediction models for depression in patients with coronary heart disease: a systematic review and meta-analysis.
Front Cardiovasc Med
January 2025
School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Background: Risk prediction models for depression in patients with coronary heart disease are increasingly being developed. However, the quality and applicability of these models in clinical practice remain uncertain.
Objective: To systematically evaluate depression risk prediction models in patients with coronary heart disease (CHD).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!